Chick ciliary ganglion neurons have a membrane component that shares an antigenic determinant with the "main immunogenic region" of the alpha subunits in nicotinic ACh receptors from skeletal muscle and electric organ. Ultrastructural studies on antibody binding in the ganglion have shown that the crossreacting antigen on the neuron surface is located predominantly in synaptic membrane. Biochemical studies have shown that the cross-reacting component has a number of other properties expected for the ganglionic nicotonic ACh receptor and that it is distinct from the a-bungarotoxin binding component in the tissue. Here we show that ciliary ganglion neurons grown in dissociated cell culture express a similar component that crossreacts with monoclonal antibodies to ACh receptors, and that the number of antibody-binding sites on the neurons can be modulated by exposure to cholinergic agonists and a protein neurotoxin that reversibly inhibits ACh receptors on the neurons. In most, though not all, cases, levels of ACh sensitivity associated with the neurons are specifically comodulated in parallel with the changes in number of antibody binding sites. The results suggest that at least a portion of the cross-reacting sites on the surface of ciliary ganglion neurons is likely to represent nicotinic ACh receptors. The fact that in some instances levels of ACh sensitivity can be altered without changing the number of cross-reacting sites, however, leaves open the possibility that not all of the sites are associated with receptors or that the neurons can alter the proportion of receptors that is functional.
Chick ciliary ganglion neurons have a membrane component that shares an antigenic determinant with the "main immunogenic region" of the alpha subunits in nicotinic ACh receptors from skeletal muscle and electric organ. Ultrastructural studies on antibody binding in the ganglion have shown that the crossreacting antigen on the neuron surface is located predominantly in synaptic membrane. Biochemical studies have shown that the cross-reacting component has a number of other properties expected for the ganglionic nicotonic ACh receptor and that it is distinct from the a-bungarotoxin binding component in the tissue. Here we show that ciliary ganglion neurons grown in dissociated cell culture express a similar component that crossreacts with monoclonal antibodies to ACh receptors, and that the number of antibody-binding sites on the neurons can be modulated by exposure to cholinergic agonists and a protein neurotoxin that reversibly inhibits ACh receptors on the neurons. In most, though not all, cases, levels of ACh sensitivity associated with the neurons are specifically comodulated in parallel with the changes in number of antibody binding sites. The results suggest that at least a portion of the cross-reacting sites on the surface of ciliary ganglion neurons is likely to represent nicotinic ACh receptors. The fact that in some instances levels of ACh sensitivity can be altered without changing the number of cross-reacting sites, however, leaves open the possibility that not all of the sites are associated with receptors or that the neurons can alter the proportion of receptors that is functional.
In contrast to the nicotinic acetylcholine receptor (AChR) of muscle and electric organ, little is known about the structure and regulation of nicotinic AChRs on neurons. Lack of suitable probes has proved to be a major obstacle in this case. a-Bungarotoxin (cr-Bgt), which binds tightly and specifically to muscle AChR, also recognizes a membrane component on many neurons having nicotinic AChRs, but the relationship of the toxin binding component to the receptor on neurons is unclear. In several cases, the evidence suggests that the toxin-binding component is distinct from the functional AChR on neurons. Thus, chick ciliary ganglion neurons have nicotinic AChRs and highaffinity cY-Bgt binding sites, but cY-Bgt fails to block ACh function on the neurons (Ravdin and Berg, 1979) , and the toxin-binding sites appear to be largely excluded from postsynaptic membrane on the neurons (Jacob and Berg, 1983; Loring et al., 1985) . In addition, the levels of ACh sensitivity and numbers of toxin binding sites can be independently regulated on the neurons in cell culture (Smith et al., 1983) , indicating that the toxin-binding site is unlikely to represent the functional, synaptic AChR on the neurons. A similar conclusion has been reached for the pheochromocytoma cell line PC1 2, for which immunological studies (Patrick and Stallcup, 1977) and developmental studies (Mitsuka and Hatanaka, 1983) suggest that the toxin-binding component is distinct from the functional nicotinic AChR on the cells.
Recently, we have used anti-AChR monoclonal antibodies (mAbs) to identify a component in chick ciliary ganglia that shares an antigenic determinant with the "main immunogenic region" (MIR) of AChR alpha subunits in muscle and electric organ. The MIR-like component has several properties expected for a nicotinic AChR on the neurons. It is an integral membrane component that sediments in detergent extracts primarily as a species of 10 S , a value close to that observed for AChR monomers from skeletal muscle and electric organ (Changeux et al., 1984) . It binds to concanavalin A, which is known to block AChR function on the neurons (Messing et al., 1984) . The component is present in detergent extracts of ciliary ganglia and sympathetic ganglia (tissues known to contain nicotinic AChRs), but not in extracts of heart, liver, spinal cord, retina, or dorsal root ganglia . The greatest increase in specific activity of the component in the ciliary ganglion occurs between embryonic days 8 and 12, a time when synapses are being consolidated on the neurons Pilar, 1972, 1978) . Ultrastructural studies in ciliary ganglia show that the mAb binding sites present on the surface of the neurons are located predominantly in synaptic membrane (Jacob et al., 1984) . The MIR-like component is distinct from the a-Bgt-binding component in the ganglion, since toxin sites have a different surface distribution (Jacob and Berg, 1983) , and toxin binding sites and mAb binding sites can be precipitated separately from ganglion extracts .
Though the MIR-like component is a strong candidate for the nicotinic AChR on ciliary ganglion neurons, a definitive demonstration has been lacking because cross-reacting mAbs do not block AChR function either in muscle or in ciliary ganglia . To examine further the relationship between the MIR-like component and the nicotinic AChR in this case, we tested the ability of cholinergic agents to comodulate the levels of anti-MIR mAb surface binding and ACh sensitivity of the neurons. Some of these results have been described in a preliminary account .
Materials and Methods Cell cultures
Ciliary ganglia from 8 d chick embryos were dissociated and grown in cell culture at 37°C on a substratum of collagen and lysed fibroblasts as previously described (Nishi and Berg, 1981a imal essential medium (MEM) containing 10% (vol/vol) heat-inactivated horse serum, 50 units/ml penicillin, and 50 &ml streptomycin. Media supplements included either embryonic chick eye extract (3% vol/vol; "eye medium"), KC1 (25 mM final concentration; "K+ medium"), or both ("K+/eye medium"), as previously described (Nishi and Berg, 198 1 b) . Unless otherwise indicated, cultures received eye medium, and the medium was replaced at 2 to 3 d intervals.
For chronic exposure of cultures to cholinergic ligands, eye medium was prepared with the indicated drugs, sterile filtered, and either supplied to the cells on days 2,4, and 6 after plating, or as indicated in the figure legends. For acute exposure, cultures were incubated with the drug in eye medium for 1 hr at 37°C on day 7. Unless otherwise indicated, antibody-binding studies were carried out on 7-d-old cultures, and electrophysiological studies on 6-or 7-d-old cultures.
Monoclonal antibodies
Hybridoma cell lines were obtained by fusing myeloma cell lines with spleen cells from rats immunized with purified muscle or electric organ AChR protein. Anti-MIR mAbs 6, 35, and 203 were raised against receptors from Torpedo (Tzartos and Lindstrom, 1980) and Electrophorus electric organ (Tzartos et al., 198 1) and human skeletal muscle , respectively. mAb 112 was raised against AChR from Torpedo electric organ and is of the same antibody subclass as mAb 35 but of different specificity: It recognizes the beta and gamma subunits, but not the alpha subunit, of the receptor ). Stocks were prepared by ammonium sulfate precipitation of hybridoma culture media. mAb 35 was purified further by chromatography on DEAE Affigel blue (S. Hochschwender, unpublished observations), and was radioiodinated by a modified chloramine T method as previously described for cu-Bgt (Lindstrom et al., 1981) to produce 1251-mAb 35 with initial specific activities of 2-3 x lOI* cpm/ mol. 'V-mAb 35 was stored at 4°C in PBS containing 0.1% sodium azide and 10 mg/ml BSA. mAb 35 binding
Cultures were rinsed once at room temperature with rinse solution containing 2 mg/ml BSA (1 ml/well; Smith et al., 1983) and then incubated for 1 hr at room temperature in 0.20 ml of solution with the same composition containing 5 nM lZ51-mAb 35 (unless otherwise indicated). The labeled cultures were then rinsed 4 x and scraped in 0.5 ml of 0.6 N NaOH for quantitating 125I with a gamma counter. Nonspecific binding, determined by including a 30-to 50-fold excess of unlabeled mAb 35 in the incubation with lZ51-mAb 35, usually constituted 20-30% of total binding and was subtracted to yield specific binding, unless otherwise indicated.
Other procedures
Neurotransmitter sensitivities were measured by using intracellular recording techniques to determine the change in membrane conductance induced by either ACh or GABA pressure-applied to the neurons from a nearby pipette. The assa'y was set up in the laboratory by J. Margiotta and has been described in detail elsewhere (Maraiotta and Benz. 1986: McEachem et al., 1985; Smith et al., 1983) :
Autoradiographic studies of mAb 35 binding to the neurons in culture were carried out by growing the neurons on glass coverslips as previously described (Jacob et al., 1984) with the indicated drugs. Cultures were labeled with lZ51-mAb 35 and rinsed as described above, fixed in 2% formaldehyde and 2% glutaraldehyde for 1 hr at room temperature, rinsed and mounted on glass slides, and processed for autoradiography (Smith et al., 1983) . Lactic acid dehydrogenase assays were performed as described by Nishi and Berg (198 la) .
Materials
Culture media components were obtained from Grand Island Biological Co., and tissue extracts and culture media were prepared as previously described (Nishi and Berg, 198 la) . Bunaarus multicinctus venom was purchased from Miami S&pentarium, and a-Bgt and Bgt 3.1 were purified from the venom as previously described (Ravdin and Berg, 1979; Ravdin et al., 198 1) . &Tubocurarine chloride, carbamylcholine chloride (carbachol), acetylcholine chloride, neostigmine bromide, and nicotine sulfate were purchased from Sigma. Trimethaphan camsylate Ro 2-2222 was the generous gift of Hoffmann-La Roche. such as mAb 6 and mAb 203, blocked the binding to the same extent as did unlabeled mAb 35, while no blockade of lZ51-mAb 35 binding occurred with mAb 112 (an mAb of the same subclass as mAb 35 but with different specificity) or with nonimmune rat serum at a comparable concentration of immunoglobulin (Fig. 3) . The number of MIR-like sites on the neuronal surface increased linearly with culture age over the 8 d period examined (Fig. 4) .
Acute modulation Bgt 3.1 is a protein neurotoxin that reversibly blocks the AChR function of ciliary ganglion neurons (Ravdin and Berg, 1979 ).
The toxin is present as a minor component in the venom of B. multicinctus and can be separated from the more common a-Bgt in the same venom (Ravdin and Berg, 1979; Ravdin et al., 198 i) . Exposure of ciliary ganglion neurons to Bgt 3.1 for 1 hr at 37°C causes the loss of about half of the MIR-like sites available to bind lZ51-mAb 35 subsequently ( modulation of surface sites cannot occur, does not reduce the amount of specific antibody binding observed (Smith et al., 1985, and unpublished observations) . Increasing the concentration of 12Y-mAb 35 threefold in the standard assay fails to detect additional sites after acute exposure of the neurons to Bgt 3.1 (data not shown). Bgt 3.1 inhibits AChR function on the neurons (Ravdin and Berg, 1979) at toxin concentrations similar to those effective here in modulating the MIR-like component. In addition, Bgt 3.1 blocks oc-Bgt binding to the neurons (Ravdin et al., 1981) . Indirect evidence (see Discussion) indicates that these two effects of Bgt 3.1 are achieved by interaction of the toxin with two distinct classes of binding sites, one being the a-Bgt binding site and the other possibly being the AChR (Ravdin et al., 1981) . We were interested in determining whether modulation of the MIR-like component by Bgt 3.1 depends on interaction with a cholinergic site and, if so, which class of sites might be important. Accordingly, we tested the ability of various cholinergic ligands to protect the MIR-like component from Bgt 3. l-induced modulation. Co-incubation of the cultures with 1O-5 M d-tubocurarine during treatment with lo-* M Bgt 3.1 completely blocked the modulation (Fig. 6 ). Other cholinergic ligands were also effective. Trimethaphan and nicotine at 1O-4 M, and carbachol and ACh at 1 mM, were each able to protect against the Bgt 3.1 effect (Fig. 7) . The protection by ACh cannot be ascribed to the accompanying neostigmine (present to prevent hydrolysis of the ACh by esterases in the culture medium) because the same concentration of neostigmine alone had no effect against the Bgt 3.1 -induced modulation. In contrast to the choline& ligands, cY-Bgt at 1O-6 M provided no protection against the Bgt 3.1 effect and did not interfere with the protection conferred by ACh. Since the concentration of cu-Bgt used represented a 50-fold excess over that needed to saturate the cr-Bgt binding site (Ravdin et al., 1981) the results indicate that the cholinergic site at which Bgt 3.1 modulates the MIR-like component is different from the ol-Bgt binding site on the neurons. None of Vol. 6, No. 4, Apr. 1986 AGONIST:
ACH Cultures were grown either in medium containing 10e8 M Bgt 3.1 (Bgt 3.1) or 10e8 M Bgt 3.1 and 10m4 M trimethaphan (Bgt 3.l/Trimet), or lo-) M carbachol (Curb), as described in Figure 9 . After rinsing extensively (eight changes of medium over a 1 hr period), the neurons were tested for ACh sensitivity (open bars) or GABA sensitivity (hatched bar), as indicated. The rinsing procedure was adequate to restore the ACh sensitivity almost completely after blockade by lo-* M Bgt 3.1 for 1 hr at 37°C and all of the ACh sensitivity after desensitization by 1 mM carbachol for 10 min at 37°C. Each determination represents the mean + SE for the number of neurons indicated in parentheses and and is expressed as the percentage of the value obtained for neurons in sister cultures grown in normal medium (eye medium). In all cases, results were compiled for neurons from at least two separate culture platings. The mean overall 100% values for ACh and GABA induced conductance changes were 32 & 3 nS (n = 8) and 30 f 5 nS (n = 8), respectively. the ligands had any significant effect by themselves on the number of lZ51-mAb 35 binding sites during the 1 hr incubation at 3 7°C.
Chronic modulation
Chronic exposure of the neurons to 10m8 M Bgt 3.1 caused an initial rapid decrease in the number of surface sites available for lZSI-mAb 35 binding. This was followed by a small and slow increase in the number of sites over a period of days (Fig. 8) .
Both cholinergic agonists and antagonists were again able to protect against modulation of the MIR-like component by chronic exposure to Bgt 3.1 (Fig. 9) . Protection by agonists, however, appeared to be incomplete. The explanation emerged from testing the agonists alone: Chronic exposure to 1 mM carbachol caused a 30% loss in the number of lz51-mAb 35 binding sites on the surface of the neurons (Fig. 9) . The decrease did not result from a change in cell size, since neurons grown with and without 1 mM carbachol appeared similar in size and had identical levels of the cytoplasmic marker enzyme, lactic acid dehydrogenase (data not shown). Thus, the number of MIR-like sites remaining after carbachol treatment was the same with or without Bgt 3.1, indicating that the agonist not only provided complete protection against the Bgt 3.1 effect, but also induced modulation of the sites independently. Smaller effects were observed with nicotine and ACh. The ganglionic antagonist trimethaphan appeared to induce a small increase in the total number of MIR-like sites on the cells.
Comodulation of ACh sensitivity
The levels of ACh sensitivity associated with the neurons after drug treatment were tested to determine whether they changed in parallel with the number of MIR-like surface sites. Chronic exposure to Bgt 3.1 followed by extensive rinsing to remove bound Bgt 3.1 resulted in levels of ACh sensitivity that were reduced to approximately the same extent as the numbers of MIR-like sites (Fig. 10) . The reduction in ACh sensitivity is likely to represent modulation rather than simple inhibition, since acute exposure of the neurons to Bgt 3.1, followed by a similar pattern of rinsing, restored nearly all of the original ACh sensitivity (Ravdin and Berg, 1979; J. Margiotta, unpublished observations) . The Bgt 3.1 effect was specific in that no reduction was observed in the levels of GABA sensitivity. Co-incubation of the neurons in 1O-4 M trimethaphan along with the Bgt 3.1 resulted in a partial protection against the modulation of ACh sensitivity. Chronic exposure to 1 mM carbachol (in the absence of Bgt 3.1) followed by extensive rinsing to remove bound carbachol and to allow for recovery from desensitization, resulted in a nearly fourfold reduction in levels of ACh sensitivity (Fig. 10) . Acute exposure to 1 mM carbachol(l0 min), followed by the same pattern of rinsing, produced no significant decrease in ACh sensitivity compared to that found for control neurons, indicating that desensitization had been reversed by the protocol (data not shown). The qualitative agreement in specific comodulation of levels of ACh sensitivity and numbers of MIR-like sites is consistent with the MIR-like component representing the nicotinic AChR on the neurons.
Exceptions to comodulation. In some instances, changes in the levels of ACh sensitivity associated with the neurons do not correlate with the numbers of 1251-mAb 35 binding sites. Acute exposure of the neurons to 1 O-' M Bgt 3.1 causes a 50% reduction in the number of mAb 35 binding sites (Fig. 5 ) and l-2 hr of rinsing does not increase the number of sites detected (M. A. Smith, unpublished observations) . The rinsing does achieve, however, a nearly complete recovery of ACh sensitivity, as cited above. A more clear-cut discrepancy is detected by examining the effects of different growth conditions. Previous studies have shown that chronic growth in medium supplemented with elevated concentrations of K+ (K+/eye medium) leads to reduced levels of ACh sensitivity for the neurons compared to that of neurons grown in normal medium (eye medium), all assayed under standard conditions (Smith et al., 1983) . lZSI-mAb 35 binding is not reduced in parallel under these conditions (Fig. 11) . Lack of correlation cannot be accounted for by a selective migration of MIR sites away from the soma when neurons are grown in elevated K+: Autoradiographs of neuronal cultures labeled with lZSI-mAb 35 indicate comparable numbers of grains associated with the somata of neurons grown in eye and K+/eye media, though they have nearly a fourfold difference in the levels of soma ACh sensitivity (Fig. 12) . The autoradiographs do show a reduced level of soma labeling by lz51-mAb 35 for neurons chronically exposed to 1O-8 M Bgt 3.1 (Fig. 12) , consistent with values for total Y-mAb 35 binding in the cultures (Figs. 8, 9 ) and for soma levels of ACh sensitivity (Fig. 10) . If neurons from K+/ eye medium are compared with neurons from K+ medium (instead of eye medium), a much better correlation is observed between relative levels of ACh sensitivity and numbers of MIRlike sites (Fig. 11) .
Discussion
Previous studies demonstrated that chick ciliary ganglion neurons in dissociated cell culture express a surface component that cross-reacts with mAbs to the MIR of muscle and electric organ AChR alpha subunits (Jacob et al., 1984) . The present studies show that the amount of the component on the neurons in culture and the specificity and Kd value for anti-MIR mAb binding are similar to those described for the solubilized MIRlike component in detergent extracts of ciliary ganglia . Fifteen day embryonic ganglia contain about 5.5 fmol of anti-MIR mAb binding sites, of which 40%, or about 2 fmol, would be expected to be on the surface of the cells if surface sites constituted the same fraction in vivo (Jacob et al., 1985) that they do in culture . Neurons from 8 d embryonic ganglia maintained in cell culture for 7 d also have about 2 fmol of surface MIR-like component per ganglion equivalent of neurons (though it should be noted that 15 d embryonic ciliary ganglia have only half as many neurons as do 8 d ganglia because of naturally occurring cell death in vivo; Landmesser and Pilar, 1974) . The major finding reported here is that specific modulation of the MIR-like component on ciliary ganglion neurons in culture can be achieved through a cholinergic site. This was shown by the action of Bgt 3.1 on the neurons, by the array of cholinergic ligands that protected against the Bgt 3.1 effect, and by the direct effects of cholinergic agonists alone. In these cases, the levels of ACh sensitivity associated with the neurons were comodulated with the number of MIR-like components on the neuron surface, as expected if the MIR-like component represents the nicotinic AChR on the cells.
Bgt 3.1 has previously been shown to recognize two classes of sites on chick ciliary ganglion neurons. Interaction of Bgt 3.1 with the first class of sites causes the specific and reversible inhibition of nicotinic AChR function on the cells. The inhibition is unaffected by the presence or absence of high concentrations of cu-Bgt, which does not itself block the neuronal AChRs (Ravdin and Berg, 1979; Ravdin et al., 1981) . Interaction of Bgt 3.1 with the second class of sites has the unusual effect of inducing the rapid internalization of cu-Bgt bound to the cells (Ravdin et al., 1981) . The second class of sites is likely to be identical with the Lu-Bgt sites themselves, since saturation of all the sites with a-Bgt prevents Bgt 3.1 from inducing intemalization of the bound Lu-Bgt, and at low temperatures, when internalization cannot occur, competition can be demonstrated between the binding of lz51-(r-Bgt and Bgt 3.1 (Ravdin et al., 198 1) . Recent electrophoretic and amino acid composition data (R. Loring and R. Zigmond, personal communication) indicate that Bgt 3.1 is identical to K-bungarotoxin (Dryer and Chiappinelli, 1983 ) and toxin F (Loring et al., 1984) all derived from B. multicinctus venom. Studies with both K-bungarotoxin (Chiappinelli, 1983) and toxin F (Loring et al., 1984) have also indicated two classes of Bgt 3.1 binding sites on ciliary ganglion neurons. In these cases, specific binding of the toxin (using a radiolabeled derivative) in the ganglion was found to be only partially blocked by Lu-Bgt. The remaining sites were comparable in number to the MIR-like sites described here, and may represent nicotinic AChRs on the neurons.
The mechanism by which Bgt 3.1 modulates the number of MIR-like sites on the neurons is unknown. The site of action, however, is likely to involve the cholinergic site on the nicotinic AChR. The fact that cholinergic agonists and antagonists are able to protect the MIR-like component against modulation by Bgt 3.1 clearly indicates that a cholinergic site is involved. The concentrations of Bgt 3.1 needed for AChR blockade and for modulation of the component are similar. The other Bgt 3.1 binding site, i.e., the site that also binds a-Bgt, is unlikely to be important for the modulation of MIR-like sites because cY-Bgt does not itself modulate the MIR-like component, and even at a 1 OO-fold excess over the Bgt 3.1 concentration, cu-Bgt is unable to protect against Bgt 3.1 -induced modulation of the component. Moreover, cu-Bgt is unable to interfere with the ability of cholinergic ligands to protect against the Bgt 3.1 -induced modulation. The simplest explanation is that the MIR-like component is the AChR, and that Bgt 3.1 induces modulation of the MIR-like component by binding to the same site that results in receptor blockade by Bgt 3.1; cholinergic ligands protect against the Bgt 3.1 effect either by competing with Bgt 3.1 for binding or by stabilizing the receptor in a resistant conformation.
The inference that the MIR-like component represents the AChR on the neurons is supported by the observation that chronic exposure of the cells to cholinergic agonists induces a decrease of about 30% in the number of MIR-like sites. The reduction is reminiscent of the commonly occurring phenomenon of agonist-induced down-regulation of receptors, and is similar in magnitude to the decrease in AChRs found with chick myotubes (32% in 72 hr) after chronic exposure to 0.1 mM carbachol (Gardner and Fambrough, 1979) . The concentrations of agonists used in the present study (1 mM) are similar to those needed to achieve maximal ACh responses from the neurons (Smith et al., 1983) . There is precedence for neuronal nicotinic AChRs having lower affinities for agonist than do muscle nicotinic AChRs (Ascher et al., 1979) .
If the MIR-like component on the neurons is the functional nicotinic AChR, changes in the number of MIR-like sites should be accompanied by similar changes in the levels of ACh sensitivity associated with the cells. This expectation was met qualitatively in several instances. Chronic exposure to Bgt 3.1 (followed by rinsing to remove the Bgt 3.1) reduced both the number of MIR-like sites and the levels of ACh sensitivity to less than a fifth of control values. GABA sensitivities were unaffected by chronic exposure to Bgt 3.1, indicating that the modulation of ACh sensitivity was specific. Co-incubation of trimethaphan along with Bgt 3.1 protected against the reduction in MIR-like sites and partially protected against the reduction in ACh sensitivity. Chronic exposure to carbachol reduced both the number of MIR-like sites and the amount of ACh sensitivity, though the latter was depressed to a greater extent. Failure to obtain quantitative agreement in some cases is not surprising in view of the inherent difficulties in using the physiological assay to assess relative numbers of functional receptors.
In three instances, however, discrepancies were observed between ACh sensitivities and MIR-like sites, and these merit further discussion. One of these is the finding that the number of MIR-like sites increases linearly with time in culture (Fig.  4) while the level of ACh sensitivity reaches a plateau value early on (Smith et al., 1983) . Another is the observation that acute exposure to Bgt 3.1, followed by extensive rinsing, results in nearly complete recovery of ACh sensitivity, while the number of MIR-like sites remains at 50%. A number of explanations could account for these first two results. The increase in MIRlike sites with time in culture, for example, might reflect receptors appearing on the neurites that would not score in the physiological assay. The acute modulation of MIR-sites by Bgt 3.1 might represent rearrangement of the sites in the membrane (e.g., clustering of receptors) that sterically hinders mAb binding without impairing receptor function. (Chronic modulation would represent subsequent internalization of the sites, accompanied by loss of receptor function and mAb binding.) Explanations of this kind, however, cannot account for the third case, i.e., the substantial discrepancy between the relative levels of ACh sensitivity and numbers of MIR-like sites for neurons grown in eye medium versus K+/eye medium. Autoradiographs confirmed that comparable labeling of neuronal somata by lZSI-mAb 35 was obtained for the two types of cultures, even though a nearly fourfold difference was observed in the levels of ACh sensitivity. Preliminary results from whole-cell patch-clamp experiments have confirmed the approximately fourfold difference in AChinduced conductance changes for neurons grown in eye versus K+/eye medium, and have also shown that the growth conditions do not cause a change in the single-channel parameters of AChRs on the cells . Though other workers did not report reduced ACh sensitivity for ciliary ganglion neurons grown in high concentrations of K+ (Bader et al., 1982 ) the methods used there would probably not have detected the fourfold difference described here.
Most of the evidence is consistent with the MIR-like component on ciliary ganglion neurons representing the nicotinic AChR. In the ganglion, the component on the surface of the neurons is located predominantly in synaptic membrane (Jacob et al., 1984) . Preliminary results indicate that intracellular MIRlike sites appear to be associated with organelles known to be part of the biosynthetic and regulatory pathways for cell-surface membrane proteins (Jacob et al., 1985) . Biochemical studies on tissues from the periphery indicate that it is restricted to tissues known to have ganglionic nicotinic AChRs, and that it has many of the properties expected for the nicotinic AChR on neurons . A polyclonal rat serum raised against a partially purified MIR-like component from chick brain (P. Whiting and J. Lindstrom, unpublished observations) that is similar to the MIR-like component in ciliary ganglia specifically blocks 85% of the ACh sensitivity associated with ciliary ganglion neurons in cell culture when applied at a 1: 100 dilution (J. Stollberg and D. Berg, unpublished observations) . The present studies demonstrate that the MIRlike site on ciliary ganglion neurons in cell culture can be modulated by cholinergic agents. In addition, changes in the number of MIR-like sites are usually associated with parallel changes in the levels of ACh sensitivity associated with the neurons. The fact that some discrepancies exist, however, in the correlation between sensitivity and site number leaves open the possibility that the component does not actually represent the nicotinic AChR, and that the considerable evidence suggesting the contrary is simply coincidence.
An alternative explanation is that only a fraction of the MIRlike sites on the neurons represents functional AChRs, and that the remainder represents either inactive receptors or some other protein. If the surface sites do include inactive AChRs, the results comparing ACh sensitivities for neurons from different growth conditions would imply that the neurons can alter or regulate the proportion of AChRs that is functional. It will be interesting to determine the types of regulation possible for neuronal nicotinic AChRs, and to obtain additional evidence concerning the relationship of the MIR-like component and the AChR on the neurons.
